If this nonsense carries on I'll be adding further. There really is no sane reason for these to be down here. |
You're right - misread it.
2,113.449 is an odd way to report a volume of shares ..... |
Nothing large there and these are just dividend reinvestment. Daily wage for most of these directors |
Director buys ... including some large ones. |
Traders betting on 8% drop in the pound. Could boost GBP reported earnings. |
GSK seems quick to buy the whole caboodle rather than project agreements where support is given and royalties paid on success.
A big issue with the industry is that once a small innovative team is bought out and merged into Big Pharma they lose that innovation and get swamped with the red tape. The only group that has managed this throughout the years has been Roche. |
13 January 2025, London UK
GSK enters agreement to acquire IDRx, Inc.
· Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)
· IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies
· Acquisition adds to GSK's growing portfolio in gastrointestinal (GI) cancers
· GSK to pay up to USD1.15BN
#PJ84, that rumour report now confirmed.. :o) |
hTTps://www.biospace.com/business/gsk-backed-ouro-launches-with-115m-to-reset-the-immune-system |
TM - that is a good move. |
Do you think GSK is a safe bet? |
IN @ 1358.8 .... ;o) |
US market closed today, so not expecting the usual 2.30pm wipe out here. |
Does this have the defensive characteristics it once had, or does it, after spinning out Haleon, have a centre of gravity that is just too close to the cutting edge of pharma? |
The U.S. Food and Drug Administration's request for a label warning about Guillain-Barre syndrome risk on GSK's respiratory syncytial virus shot Arexvy could negatively impact vaccine sales, Bryan Garnier Research analysts say in a note. While a causal link between vaccination and GBS-- a rapid-onset muscle weakness caused by the immune system-- hasn't been proven, seven GBS cases per million Arexvy doses were observed, according to the FDA. "We believe the observed GBS incidence very close to natural GBS incidence in the non-vaccinated population," the analysts say. Arexvy sales already declined double-digit in 2H of 2024, following the narrowed recommendation to a smaller age range and more at-risk patients, the analysts say. Shares fall 0.04% at 1359.50 pence |
#892. More bought in R&D which will go on the Balance Sheet and not impact profits. Remember, it will have to be amortised at some date.
GSK needs to have much more home grown R&D from its extensive in-house facilities. |
Dividends reached my AJ Bell accounts this morning .... ;0) |
*GSK NEARS $1BN DEAL FOR BIOTECH IDRX DEVELOPING DRUG FOR RARE TUMOUR- FT |
However, the available evidence was insufficient to establish a causal relationship, the FDA said.
(The risks flagged in the prescribing information of GSK's Arexvy and Pfizer's Abrysvo were not the regulator's strictest "boxed" warnings.) |
 Not going to help sentiment sadly..
"GSK, Pfizer RSV shots to get warning of rare neurological disorder"
The U.S. FDA is ordering that respiratory syncytial virus (RSV) vaccines marketed by GSK (NYSE:GSK) and Pfizer (NYSE:PFE) contain a warning on labeling of the risk of developing the rare neurological disorder Guillain-Barré syndrome ("GBS").
The FDA Safety Communication impacts GSK's Arexvy and Pfizer's Abrysvo.
The agency said it made the decision based on post-marketing observational studies of the two shots, as well as adverse event reports.
Analyses of all GBS cases based on claims data suggest an increased risk of the disease during the 42 days following vaccination, with an estimated nine excess cases of GBS per million doses of Abrysvo, and seven excess cases per million doses of Arexvy, according to the FDA.
With GBS, an individual's immune system wrongly attacks part of their peripheral nervous system, which carries signals from the brain and spinal cord to the rest of the body. |
15p/share dividend pays out tomorrow ..... ;0) |
Well at this embarrassingly low share price I've sold a few other holdings and added to my GSK today. |
More good news for GSK
"GSK ADC gets FDA breakthrough therapy designation"
GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
And yet sentiment in stock seems unmovable.
Tempted to buy myself. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
